Cabergoline

卡麦角林

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameCabergoline
Drug Alias NameCabergolinaCabergolinumSogilenDostinexCabaseril +[9
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonists
TargetsDopamine receptors
Therapy Area/IndicationsCocaine-Related DisordersSubstance-Related DisordersBody Weight +[17
Global Approved IndicationsHyperprolactinemiaParkinson Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date1992/01/01
Country/TerritoryUnited StatesSwedenNorway +[7
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active IndicationsGalactorrheaAbortion, SpontaneousInfertility, Female +[9
Inactive IndicationsCocaine-Related DisordersSubstance-Related DisordersBody Weight +[8

Other Information

ATC CodeG02CB03N04BC06